Arena Pharma (ARNA) Reports In-Line Q4 Loss; Offers FY16 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. USO
7. STZ
8. CRGY
9. AAPL
10. SPY

Go back to Arena Pharma (ARNA) Reports In-Line Q4 Loss; Offers FY16 Outlook

Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

February 29, 2016 4:00 PM EST

SAN DIEGO, Feb. 29, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2015, and provided a corporate update.

"Arena took a number of important steps in 2015, including initiating two Phase 2 clinical trials, partnering two of our programs, filing a new drug application and reducing our internal expenses," said Harry F. Hixson, Jr., Arena's interim Chief Executive Officer. "We entered 2016 focused on advancing our internal and partnered clinical-stage compounds that we believe will highlight the intrinsic value of our... More